Cns Pharmaceuticals, INC DEF 14A proxy statements

CNS Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for September 30, 2026, to elect directors, ratify auditors, and seek approval for amendments to its 2020 Stock Plan.

CNS Pharmaceuticals, Inc. filed a supplement to its proxy statement to correct an error on the proxy card related to the 'say-on-pay' frequency vote for its upcoming November 17, 2025 annual meeting.

CNS Pharmaceuticals, Inc. will hold its Annual Meeting on November 17, 2025, seeking stockholder approval for key proposals including a significant increase in authorized shares and re-election of directors.

CNS Pharmaceuticals has amended its reverse stock split proposal to provide cash payments instead of fractional shares to stockholders.

CNS Pharmaceuticals is holding a special meeting to seek stockholder approval for a reverse stock split and warrant repricing to comply with Nasdaq listing requirements.

CNS Pharmaceuticals is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and the repricing of certain warrants.